Combining presbyopia correction and astigmatism control in one IOL

Article

Oculentis presented its multifocal toric intraocular lens, the LENTIS Mplustoric at ESCRS in Paris.

Oculentis presented its multifocal toric intraocular lens, the LENTIS Mplustoric at ESCRS in Paris. The new IOL offers Oculentis's award winning presbyopia correction combined with the astigmatism correction from LENTIS Tplus technology.

Patrick Reinhold, product manager, said that the company offers: "Big innovation in multifocal IOLs with the LENTIS Mplustoric as it features a segment at the bottom of the lens that reduces halos and glare." This sector-shaped near vision segment is reported to also offer advantages to the patient in reflections, image jumps and loss of contrast sensitivity, currently occurring with available 'ring' systems, as well as the inhibition of ghost images and/or double vision.

The toric MIOL is made from HydroSmart acrylic materials and allows pupil independence, aberration neutrality and the addition of 3.0 and 1.5 dioptres. It can also be tailor-made to benefit patients suffering from both presbyopia and corneal astigmatism. The predefined inferior placement of the near vision segment and the customized torus simplify the orientation and implantation procedure of the toric MIOL.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.